Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Masahiro Ashizawa"'
Autor:
Masaharu Tamaki, Yu Akahoshi, Masahiro Ashizawa, Yukiko Misaki, Satoshi Koi, Sung-Won Kim, Yukiyasu Ozawa, Shin-ichiro Fujiwara, Shinichi Kako, Ken-ichi Matsuoka, Masashi Sawa, Yuta Katayama, Makoto Onizuka, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Kimikazu Yakushijin, Hideki Nakasone
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Allogeneic hematopoietic cell transplantation between female donors and male recipients (female-to-male allo-HCT) is a well-established risk factor for inferior survival outcomes due to a higher incidence of graft-versus-host disease (GVHD).
Externí odkaz:
https://doaj.org/article/854cda6ed879453093573fa734c2550c
Autor:
Chihiro Yamamoto, Hirotomo Nakashima, Takashi Ikeda, Shin-ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Takashi Nagayama, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Miyuki Sugimoto, Yuko Ishihara, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Shin-ichiro Fujiwara, Masuzu Ueda, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
Publikováno v:
Blood Advances, Vol 3, Iss 21, Pp 3266-3277 (2019)
Abstract: The cost of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) is a substantial economic burden. In Japan, imatinib, dasatinib, and nilotinib are now approved as first-line treatment of CML in chronic phase
Externí odkaz:
https://doaj.org/article/457d89f637d1478bad0cfb53f35c1dde
Autor:
Kiyomi Mashima, Iekuni Oh, Ken Fujiwara, Junko Izawa, Norihito Takayama, Hirofumi Nakano, Yasufumi Kawasaki, Daisuke Minakata, Ryoko Yamasaki, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Shin-Ichiro Fujiwara, Nobuhiko Ohno, Yoshinobu Kanda
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0245232 (2021)
Graft-versus-host disease is a major complication after allogeneic hematopoietic stem cell transplantation for hematological malignancies. Immunosuppressive drugs, such as anti-thymocyte globulin, alemtuzumab, and post-transplant cyclophosphamide, ha
Externí odkaz:
https://doaj.org/article/0aaa237dce9444c39147d32e9e85fd09
Autor:
Kana Sakamoto, Hideki Nakasone, Hidenori Wada, Ryoko Yamasaki, Yuko Ishihara, Koji Kawamura, Masahiro Ashizawa, Miki Sato, Kiriko Terasako-Saito, Tomohito Machishima, Shun-ichi Kimura, Misato Kikuchi, Shinichi Kako, Junya Kanda, Rie Yamazaki, Aki Tanihara, Junji Nishida, Yoshinobu Kanda
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e73754 (2013)
BACKGROUND: Preemptive therapy with ganciclovir (GCV) based on the results of a cytomegalovirus (CMV) antigenemia assay is a standard strategy for preventing CMV disease after allogeneic hematopoietic cell transplantation (HCT). However, the appropri
Externí odkaz:
https://doaj.org/article/3f5bf9431cf0458585ab03a1d3d09fe0
Autor:
Daisuke Minakata, Shin‐ichiro Fujiwara, Daizo Yokoyama, Atsuto Noguchi, Shuka Aoe, Takashi Oyama, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Takashi Ikeda, Shin‐ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda
Publikováno v:
British Journal of Haematology. 200:694-703
Autor:
Takashi Nagayama, Shin-ichiro Fujiwara, Tomohiro Kikuchi, Kaoru Onda, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, Sae Matsuoka, Shin-ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Tetsuaki Ban, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Yoshinobu Kanda
Publikováno v:
Leukemia & Lymphoma. 63:1694-1700
The definition of sarcopenia assessed by computed tomography (CT) varies among different reports, and few studies have examined the effect of muscle mass loss on the prognosis of post-hematopoietic cell transplantation (HCT). We retrospectively evalu
Autor:
Chihiro Yamamoto, Daisuke Minakata, Daizo Yokoyama, Shuka Furuki, Atsuto Noguchi, Shunsuke Koyama, Takashi Oyama, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, Shin-ichiro Kawaguchi, Kazuki Hyodo, Yumiko Toda, Shoko Ito, Takashi Nagayama, Kento Umino, Kaoru Morita, Masahiro Ashizawa, Masuzu Ueda, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Shin-ichiro Fujiwara, Yoshinobu Kanda
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a8f5a7bffce7c70403932d02d28ff67
https://doi.org/10.2139/ssrn.4361264
https://doi.org/10.2139/ssrn.4361264
Autor:
Yuta Takahashi, Shinichi Kako, Masahiro Ashizawa, Yoshinobu Kanda, Shun-ichi Kimura, Noriko Oyama-Manabe, Keiko Akahane, Masahiro Kawahara, Satoru Takahashi, Shogo Hatanaka, Katsuyuki Shirai, Masaru Wakatsuki, Kazunari Ogawa, Masato Suzuki
Publikováno v:
Journal of Radiation Research
Total body irradiation (TBI) with ovarian shielding is expected to preserve fertility among hematopoietic stem cell transplant (HSCT) patients with myeloablative TBI-based regimens. However, the radiation dose to the ovaries that preserves ovarian fu
Autor:
Shin-ichiro Fujiwara, Rui Murahashi, Hirotomo Nakashima, Sae Matsuoka, Takashi Ikeda, Yumiko Toda, Shoko Ito, Shin-ichiro Kawaguchi, Takashi Nagayama, Kento Umino, Daisuke Minakata, Kaoru Morita, Hirofumi Nakano, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda
Publikováno v:
Leukemia research. 121
Cardiotoxicity after allogeneic stem cell transplantation (SCT) is associated with a high rate of mortality and worsening quality of life. The relation between daunorubicin dose and post- allogeneic stem cell transplantation (SCT) cardiotoxicity rema
Autor:
Hirotomo Nakashima, Shin-Ichiro Kawaguchi, Shin-ichiro Fujiwara, Iekuni Oh, Yumiko Toda, Hirofumi Nakano, Takashi Nagayama, Ken Ohmine, Kento Umino, Sae Matsuoka, Takashi Ikeda, Rui Murahashi, Ryoko Yamasaki, Yoshinobu Kanda, Chihiro Yamamoto, Masahiro Ashizawa, Kazuya Sato, Shoko Ito, Tetsuaki Ban, Daisuke Minakata, Kaoru Hatano
Publikováno v:
International Journal of Hematology. 114:79-84
High-dose methotrexate (MTX) is widely used for the treatment of hematological malignancies. Despite the application of routine supportive care measures, such as intensive fluid hydration and urine alkalinization, nephrotoxicity is still a problem. T